DNA X, Inc. — fact timeline

DNA X, Inc. terminated Registration Rights Agreement with Chardan Capital Markets LLC (effective 2026-05-28).

“On May 29, 2026, the Company and Chardan entered into a letter agreement pursuant to which they agreed, among other things, to terminate, effective as of 5:00 p.m., New York City time, on May 28, 2026, the ChEF Agreement and Registration Rights Agreement.”

DNA X, Inc. terminated ChEF Purchase Agreement with Chardan Capital Markets LLC valued at up to $500 million (effective 2026-05-28).

“On May 29, 2026, the Company and Chardan entered into a letter agreement pursuant to which they agreed, among other things, to terminate, effective as of 5:00 p.m., New York City time, on May 28, 2026, the ChEF Agreement and Registration Rights Agreement.”

DNA X, Inc. issued convertible note to DNA Holdings Venture, Inc. for aggregate purchase price of $3,052,787.68.

“On May 20, 2026, DNA X, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with DNA Holdings Venture, Inc. (the “Purchaser”) pursuant to which the Company sold and issued to the Purchaser a convertible promissory note (the “Note”) in the principal amount of $3,052,787.68 for an aggregate purchase price in the same amount. The transactions contemplated by the Purchase Agreement, including the issuance of the Note, were consummated on May 26, 2026.”

DNA X, Inc. amended Amendment No. 1 to the Membership Interest Purchase Agreement with DNA Holdings Venture, Inc..

“the Company and the Purchaser entered into an Amendment No. 1 to the Membership Interest Purchase Agreement (the “Purchase Agreement Amendment”) pursuant to which the Company and the Purchaser agreed to terminate the “Put Option” described therein, effective as of the execution of the Purchase Agreement.”

DNA X, Inc. entered into Securities Purchase Agreement with DNA Holdings Venture, Inc. valued at $3,052,787.68 (effective 2026-05-20).

“On May 20, 2026, DNA X, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with DNA Holdings Venture, Inc. (the “Purchaser”) pursuant to which the Company sold and issued to the Purchaser a convertible promissory note (the “Note”) in the principal amount of $3,052,787.68 for an aggregate purchase price in the same amount.”

DNA X, Inc. incurred convertible notes of $3,052,787.68 with DNA Holdings Venture, Inc. at 10% per annum maturing December 31, 2026.

“On May 20, 2026, DNA X, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with DNA Holdings Venture, Inc. (the “Purchaser”) pursuant to which the Company sold and issued to the Purchaser a convertible promissory note (the “Note”) in the principal amount of $3,052,787.68”

DNA X, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

“May 22, 2026, the Company received a delisting determination letter from the Staff advising the Company that unless the Company requests a hearing before a Nasdaq Hearing Panel (the “Panel”) to appeal Nasdaq’s delisting”

DNA X, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

“May 22, 2026, the Company received a delisting determination letter from the Staff advising the Company that unless the Company requests a hearing before a Nasdaq Hearing Panel (the “Panel”) to appeal Nasdaq’s delisting”

DNA X, Inc. reported first quarter ended March 31, 2026 results: revenue There was no revenue from continuing operations because revenue from our phone and hotspot operations was included in di, net income $6.3 million in net income for the first quarter of 2026.

“DNA X, Inc. Reports First Quarter 2026 Financial Results ● Closed sale of the Company’s mobile device assets to NEXA in January 2026 ● Completed the transfer of the operations of the phone and hotspot business to NEXA ● Focused on enhancing the DNA X trading platform to prepare the platform for its initial growth phase”

DNA X, Inc. engaged TAAD LLP as its auditor.

“On April 27, 2026, the Audit Committee approved the engagement of TAAD LLP (“TAAD”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”

DNA X, Inc. dismissed Baker Tilly US, LLP as its auditor.

“On April 27, 2026, the Audit Committee of the Board of Directors (the “Audit Committee”) of DNA X, Inc. (the “Company”) dismissed Baker Tilly US, LLP (“Baker Tilly”) as the Company’s independent registered public accounting firm.”

DNA X, Inc. reported the fourth quarter and full year ended December 31, 2025 results: revenue There was no revenue from continuing operations.

“On April 14, 2026, DNA X, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended December 31, 2025”

DNA X, Inc.: Changed corporate name to DNA X, Inc. via certificate of amendment to certificate of incorporation (effective 2026-01-23).

“On the Closing Date, the Company changed its corporate name to DNA X, Inc. pursuant to a certificate of amendment to the Company’s amended and restated certificate of incorporation (the “ Charter Amendment ”) filed with the Delaware Secretary of State on January 23, 2026 (the “ Name Change ”).”

DNA X, Inc. terminated February Note with Streeterville Capital, LLC valued at approximately $5.4 million.

“On the Closing Date, the Company prepaid (i) that certain promissory note (the “ July Note ”), dated July 11, 2025, issued by the Company to Streeterville Capital, LLC (the “ Lender ”), pursuant to that certain note purchase agreement, dated July 11, 2025, by and between the Company and the Lender and (ii) that certain promissory note (the “ February Note ” and, together with the July Note, the “ Notes ”), dated February 21, 2025, issued by the Company to the Lender, pursuant to that certain note purchase agreement, dated February 21, 2025, by and between the Company and the Lender.”

DNA X, Inc. terminated July Note with Streeterville Capital, LLC valued at approximately $5.4 million.

“On the Closing Date, the Company prepaid (i) that certain promissory note (the “ July Note ”), dated July 11, 2025, issued by the Company to Streeterville Capital, LLC (the “ Lender ”), pursuant to that certain note purchase agreement, dated July 11, 2025, by and between the Company and the Lender and (ii) that certain promissory note (the “ February Note ” and, together with the July Note, the “ Notes ”), dated February 21, 2025, issued by the Company to the Lender, pursuant to that certain note purchase agreement, dated February 21, 2025, by and between the Company and the Lender.”

DNA X, Inc. amended APA Amendment with the Buyer, the Parent, and the Seller Representative.

“On the Closing Date, the Company, the Buyer, the Parent, and the Seller Representative entered into a second amendment to the Asset Purchase Agreement (the “ APA Amendment ”).”

DNA X, Inc. completed a disposition involving Pace Car Acquisition LLC (closed 2026-01-23).

“the completion on January 23, 2026 (the “ Closing Date ”) of the previously announced sale (the “ Asset Sale ”) of substantially all of its assets related to the enterprise 5G solutions business, including rugged handsets, smartphones, wireless internet device, software, services, and accessories by DNA X, Inc. (formerly, Sonim Technologies, Inc.), a Delaware corporation (the “ Company ”), to Pace Car Acquisition LLC, (the “ Buyer ”)”

DNA X, Inc. entered into Membership Interest Purchase Agreement with DNA Holdings Venture, Inc. valued at 223,201 shares of the Company’s common stock, representing 19.99% of the outstanding shares (effective 2025-12-15).

“for an aggregate purchase price of 223,201 shares of the Company’s common stock, representing 19.99% of the outstanding shares of the Company’s common stock”

DNA X, Inc. entered into Purchase Agreement with DNA Holdings Venture, Inc. valued at $1,200,000 (effective 2025-12-15).

“On December 15, 2025, Sonim Technologies, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with DNA Holdings Venture, Inc. (“DNA Holdings”) and issued a convertible promissory note in the original principal amount of $1,200,000 (the “DNA Note”)”

DNA X, Inc. issued 18,423 shares of common stock of common stock to 13D Management, LLC for exchange of $180,000 of the Note.

“November 17, 2025 18,423 shares of common stock in consideration of the exchange of $180,000 of the Note.”

DNA X, Inc. issued 16,187 shares of common stock of common stock to 13D Management, LLC for exchange of $180,000 of the Note.

“October 31, 2025 16,187 shares of common stock in consideration of the exchange of $180,000 of the Note.”

DNA X, Inc. issued 148,500 shares of common stock of common stock to 13D Management, LLC for exchange of $629,640 of the Note.

“December 16, 2025 148,500 shares of common stock in consideration of the exchange of $629,640 of the Note.”

DNA X, Inc. issued 223,201 shares of common stock of common stock to DNA Holdings Venture, Inc. for exchange of the membership interest in DNA X.

“December 15, 2025 223,201 shares of common stock in consideration of the exchange of the membership interest in DNA X.”

DNA X, Inc. issued convertible note to DNA Holdings Venture, Inc. for $1,200,000.

“On December 15, 2025, Sonim Technologies, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with DNA Holdings Venture, Inc. (“DNA Holdings”) and issued a convertible promissory note in the original principal amount of $1,200,000 (the “DNA Note”), in a private placement (the “Offering”).”

DNA X, Inc. incurred convertible notes of $1,200,000 with DNA Holdings Venture, Inc. at 10% per annum maturing December 15, 2026.

“issued a convertible promissory note in the original principal amount of $1,200,000 (the “DNA Note”)”

DNA X, Inc. completed an acquisition involving DNA Holdings Venture, Inc. for 223,201 shares of the Company’s common stock, representing 19.99% of the outstanding shares of the Company’s common stock as of the date of issuance (closed 2025-12-15).

“the Company purchased 100% of the membership interests in DNA X LLC, a Delaware limited liability company, (“DNA X”) for an aggregate purchase price of 223,201 shares of the Company’s common stock, representing 19.99% of the outstanding shares of the Company’s common stock as of the date of issuance.”

DNA X, Inc. amended APA Amendment with Pace Car Acquisition LLC, Social Mobile Technology Holdings LLC, and the Seller Representative (effective 2025-11-24).

“On November 24, 2025, the Company, the Buyer, the Parent, and the Seller Representative entered into a first amendment to the Purchase Agreement (the “APA Amendment”).”

DNA X, Inc. issued common stock.

“The Certificate of Amendment will become effective at 12:01 a.m. Eastern Time on October 27, 2025, at which time every eighteen (18) shares of Common Stock will be automatically combined into one (1) issued and outstanding share of Common Stock, without any change in par value per share.”

DNA X, Inc.: Approved and effected a 1-for-18 reverse stock split of common stock via a certificate of amendment to the amended and restated certificate of incorporation (effective 2025-10-27).

“On October 20, 2025, the Company filed a certificate of amendment to the Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware to effect the Reverse Stock Split. The Certificate of Amendment will become effective at 12:01 a.m. Eastern Time on October 27, 2025, at which time every eighteen (18) shares of Common Stock will be automatically combined into one (1) issued and outstanding share of Common Stock, without any change in par value per share.”

DNA X, Inc.: Amendment to increase authorized shares from 100,000,000 to 1,000,000,000 (effective 2025-10-16).

“On October 16, 2025, the Company effected the Authorized Share Proposal by filing a certificate of amendment to the Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware, effective as of such date.”

DNA X, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“October 17, 2025, the Company received written notification from Nasdaq (the “Extension Notice”) granting the Company an extension through December 31, 2025, to regain compliance with Nasdaq Listing Rule 5550(b)(1). Under the terms of the extension, on or before December 31, 2025, the Company must evidence compliance with Nasdaq Listing Rule 5550(b)(1) as set forth in the Extension Notice. The Company intends to satisfy these requirements within the current extension period or, if necessary, to request a further extension from Nasdaq, which would be subject to Nasdaq’s discretion. The Company”

DNA X, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).

“October 17, 2025, the Company received written notification from Nasdaq (the “Extension Notice”) granting the Company an extension through December 31, 2025, to regain compliance with Nasdaq Listing Rule 5550(b)(1). Under the terms of the extension, on or before December 31, 2025, the Company must evidence compliance with Nasdaq Listing Rule 5550(b)(1) as set forth in the Extension Notice. The Company intends to satisfy these requirements within the current extension period or, if necessary, to request a further extension from Nasdaq, which would be subject to Nasdaq’s discretion. The Company”

DNA X, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1), 5550(b)(2), 5550(b)(3)).

“August 22, 2025, Sonim Technologies, Inc. (the “Company”) received a letter (the “Deficiency Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s stockholders’ equity, as reported in its Quarterly Report on Form 10-Q for the period ended June 30, 2025 (the “Form 10-Q”), did not satisfy the continued listing requirement under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Market, which requires that a listed company’s stockholders’ equity be at least $2.5 million. As reported on its Form 10-Q, the Company’s stockholders’ equity as of June 30, 2025 was $1,334”

DNA X, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“August 13, 2025, Sonim Technologies, Inc. (the “Company”) received a letter (the “Notice”) from the listing qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) for continued listing. The Bid Price Rule requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) (the “Compliance Period Rule”) provides that a failure to meet the minimum bid price requirement ex”

DNA X, Inc. incurred debt of €3 million with Tradewind GmbH at the greater of 4.00% or EURIBOR plus 3.50% maturing twelve (12) months, subject to an automatic annual extension, unless terminated.

“Tradewind will provide receivables factoring to the Company. Pursuant to the terms of the Factoring Agreement, eligible receivables will be purchased by Tradewind at a 15% discount to their face value. The maximum financing amount of the factoring facility is €3 million.”

DNA X, Inc. incurred senior notes of $2,755,000 with Streeterville Capital, LLC at nine percent (9%) per annum maturing eighteen (18) months following the date of issuance.

“On July 11, 2025, Sonim Technologies, Inc. (the “Company”) entered into a note purchase agreement (the “Purchase Agreement”) with Streeterville Capital, LLC (the “Lender”) pursuant to which the Company issued and sold to the Lender a promissory note in the original principal amount of $2,755,000 (the “Note”).”

DNA X, Inc. engaged Baker Tilly US, LLP as its auditor.

“the Audit Committee of the Company’s Board of Directors approved the appointment of Baker Tilly, as the successor to Moss Adams, as the Company’s independent registered public accounting firm.”

Moss Adams LLP resigned as auditor of DNA X, Inc..

“Moss Adams has resigned as the auditors of the Company, and the Audit Committee of the Company’s Board of Directors approved the appointment of Baker Tilly, as the successor to Moss Adams, as the Company’s independent registered public accounting firm.”

DNA X, Inc. incurred loan of $3,300,000 with Streeterville Capital, LLC at nine percent (9%) per annum maturing eighteen (18) months following the date of issuance.

“On February 21, 2025, Sonim Technologies, Inc. (the “Company”) entered into a note purchase agreement (the “Purchase Agreement”) with Streeterville Capital, LLC (the “Lender”) pursuant to which the Company issued and sold to the Lender a promissory note in the original principal amount of $3,300,000 (the “Note”).”

DNA X, Inc. reported the quarter ended March 31, 2024 results: revenue $16.8 million, net income $2.9 million.

“Sonim Technologies, Inc . (Nasdaq: SONM) , a leading provider of mobility solutions that include ultra-rugged and rugged phones, connected devices, consumer durable mobile devices, and accessories designed to provide extra protection for users that demand more durability in their work and everyday lives, reported financial results for the quarter ended March 31, 2024. First Quarter 2024 and Recent Highlights ● Net revenues increased by 25% sequentially, to $16.8 million ● GAAP net loss for the quarter was $2.9 million, compared to net loss of $1.4 million in the fourth quarter 2023 due to sales product mix.”

DNA X, Inc. entered into Lock-Up Agreement with the Purchaser (effective 2024-04-29).

“In addition, on April 29, 2024, in connection with the entry into the Subscription Agreement, the Company and the Purchaser entered into a lock-up agreement (the “Lock-Up Agreement”).”

DNA X, Inc. entered into Registration Rights Agreement with the Purchaser (effective 2024-04-29).

“On April 29, 2024, in connection with the entry into the Subscription Agreement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Purchaser.”

DNA X, Inc. entered into Subscription Agreement with an individual investor (the Purchaser) valued at $3,850,000 (effective 2024-04-29).

“On April 29, 2024, Sonim Technologies, Inc. (the “Company”) entered into a subscription agreement (the “Subscription Agreement”) with an individual investor identified in the Subscription Agreement (“Purchaser”), providing for the private placement of (i) 3,500,000 shares of the Company’s common stock, par value $0.001, (“Common Stock”) and (ii) warrants to purchase up to 3,500,000 shares of Common Stock (the “Warrants”) for an aggregate purchase price of $3,850,000 (the “Purchase Price”).”

DNA X, Inc. reported the fiscal year ended December 31, 2023 results: revenue $93.6 million, net income $90 thousand.

“Full Year 2023 and Recent Highlights ● Net revenues increased by 34% year-over-year, to $93.6 million, up from $69.8 million in 2022 ● GAAP net loss for the full year improved to $90 thousand, down from a net loss of $14.1 million in 2022”

DNA X, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“March 13, 2024, Sonim Technologies, Inc. (the “Company”) received formal notice that The Nasdaq Stock Market, LLC (“Nasdaq”) granted the Company’s request for an additional 180-day period, or until September 9, 2024, (the “Extension Notice”) from the Listing Qualifications Department (the “Staff”) to evidence compliance with the $1.00 per share requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”). If at any time before September 9, 2024, the bid price of the Company’s common stock closes at $1.00 per share or”

DNA X, Inc. reported the third quarter ended September 30, 2023 results: revenue $27.6 million, net income $527 thousand.

“the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. --- EX-99.1 () --- EX-99.1 2 ex99-1.htm Exhibit 99.1 Sonim Reports 34% Revenue Increase to $27.6 Million, Continued GAAP Profitability in Third Quarter 2023 Increased Gross Margin, Continued GAAP Net Income Demonstrate Durability of Sonim Financial Model Growing List of New Tier-One”

DNA X, Inc. shareholders approved Approval of amendment to the Plan to increase aggregate number of shares of common stock authorized for issuance by 2,000,000 shares at the 2023-09-28 meeting.

“Proposal 3: The stockholders approved an amendment to the Plan to increase the aggregate number of shares of common stock authorized for issuance by 2,000,000 shares, as follows: Votes Against Votes Abstained Broker Non-Votes 21,214,229 2,361,341 30,737 6,788,012”

DNA X, Inc. shareholders approved Ratification of appointment of Moss Adams LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-09-28 meeting.

“Proposal 2: The stockholders, on an advisory basis, ratified the appointment of Moss Adams LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, as follows: Votes Against Votes Abstained Broker Non-Votes 30,231,684 137,903 24,732 N/A”

DNA X, Inc. shareholders approved Election of five director nominees to the Board of Directors at the 2023-09-28 meeting.

“The Annual Meeting was held on September 28, 2023. Holders of 30,394,319 shares of the Company’s common stock were represented at the meeting in person or by proxy, constituting a quorum. The following are the voting results on each matter submitted to the stockholders of the Company at the Annual Meeting. Proposal 1: The stockholders elected each of the five director nominees to the Board of Directors of the Company to serve until the next annual meeting and until his or her successor has been duly elected and qualified, as follows: Name Votes Withheld Broker Non-Votes James Cassano 22,559,091 1,040,013 6,795,215 Peter Liu 23,452,354 153,953 6,788,012 Mike Mulica 21,565,460 2,040,805 6,788,054 Jack Steenstra 21,547,809 2,051,253 6,795,257 Jeffrey Wang 23,399,954 206,353 6,788,012”

DNA X, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“September 14, 2023, Sonim Technologies, Inc. (the “Company”) received a letter (the “Notice”) from the listing qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) for continued listing. The Bid Price Rule requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) (the “Compliance Period Rule”) provides that a failure to meet the minimum bid price requirement”